Published in Clin Cancer Res on October 01, 2005
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer (2007) 0.92
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80
Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica (2016) 0.78
Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci (2015) 0.76
A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncol Rep (2015) 0.76
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11(+) or -A33(+) allele. Cancer Sci (2017) 0.75
A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. Exp Ther Med (2010) 0.75
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65
Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother (2005) 1.47
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci (2006) 1.41
Dry box training with three-dimensional vision for the assistant surgeon in robot-assisted urological surgery. Int J Urol (2013) 1.40
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23
Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother (2012) 1.16
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15
A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. Rare Tumors (2009) 1.14
Enhancement of intervertebral disc cell senescence by WNT/β-catenin signaling-induced matrix metalloproteinase expression. Arthritis Rheum (2010) 1.13
Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One (2013) 1.11
Effect of cell number on mesenchymal stem cell transplantation in a canine disc degeneration model. J Orthop Res (2010) 1.11
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother (2012) 1.10
Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol (2004) 1.09
Next-generation peptide vaccines for advanced cancer. Cancer Sci (2012) 1.09
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07
Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol (2008) 1.06
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol (2012) 1.03
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother (2009) 1.02
A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother (2002) 1.01
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci (2007) 1.00
In vitro micronucleus assay for cigarette smoke using a whole smoke exposure system: a comparison of smoking regimens. Exp Toxicol Pathol (2009) 0.99
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol (2013) 0.99
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci (2003) 0.98
Cloning of mouse Cited4, a member of the CITED family p300/CBP-binding transcriptional coactivators: induced expression in mammary epithelial cells. Genomics (2002) 0.98
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate (2007) 0.98
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother (2003) 0.98
Multifarious control of two-photon excitation of multiple fluorophores achieved by phase modulation of ultra-broadband laser pulses. Opt Express (2009) 0.97
Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol (2011) 0.97
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother (2006) 0.97
Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother (2011) 0.97
The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer. Mol Cancer Ther (2013) 0.96
Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer (2010) 0.96
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (2010) 0.96
Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol (2002) 0.95
Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer (2011) 0.95
Role of the CD5 molecule on TCR gammadelta T cell-mediated immune functions: development of germinal centers and chronic intestinal inflammation. Int Immunol (2003) 0.94
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate (2005) 0.94
Immediate early genes expressed in chlorovirus infections. Virology (2004) 0.94
Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) (2011) 0.94
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med (2011) 0.93
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother (2003) 0.92
Anti-influenza virus compound from Streptomyces sp. RI18. Org Lett (2010) 0.92
A case of small cell carcinoma of the kidney. Hinyokika Kiyo (2007) 0.92
Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer (2002) 0.92
Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum Immunol (2004) 0.91
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine (2007) 0.91
The relationship between the Wnt/β-catenin and TGF-β/BMP signals in the intervertebral disc cell. J Cell Physiol (2011) 0.90
MR measurement of visceral fat: assessment of metabolic syndrome. Magn Reson Med Sci (2006) 0.90
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother (2005) 0.90
Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res (2004) 0.90
Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer (2002) 0.90
Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat (2011) 0.90
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci (2014) 0.90
Scattering functions of knotted ring polymers. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 0.90
Agile parallel bioinformatics workflow management using Pwrake. BMC Res Notes (2011) 0.89
Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus. Virology (2008) 0.89
Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol (2014) 0.89
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells. J Bone Miner Res (2004) 0.89
Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy. Int J Urol (2013) 0.89
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep (2011) 0.89
Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med (2007) 0.88